Time related inhibition by methylguanidine in LPS-stimulated J774A.1 macrophages

Pharmacologyonline

Volumn 2, Issue , 2013, Pages 43-49

  Marzocco, Stefania ^a   Adesso, Simona ^a   Autore, Giuseppina ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

COX 2; Macrophages; Methylguanidine; Uremia

Indexed keywords

CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; METHYLGUANIDINE; N(G) NITROARGININE METHYL ESTER; PROSTAGLANDIN E2;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ESCHERICHIA COLI; IMMUNE RESPONSE; IMMUNOMODULATION; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION;

EID: 84884218004     PISSN: None     EISSN: 18278620     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Mason MF, Resnik H, Jr Minot AS, Rainey J, Pilcher C, Harrison TR. Mechanism of experimental uremia. Archives of Internal Medicine 1937; 60, 3 12-336
2. Balestri PL, Barsotti G, Camici M, Giovannetti S. High plasma fibrinogen levels and reduced fibrinolytic activity in dogs intoxicated with methylguanidine. Clinical Nephrology 1974; 2,8143
3. Giovannetti S, Biagini M, Balestri PL, Navalesi R, Giagnoni P, DeMatteis A, Ferro-Milone P, Perfetti C. Uraemia-like syndrome in dogs chronically intoxicated with methylguanidine and creatinine. Clinical Science 1969; 36 445-452
4. Vanholder R, Argiles A, Baurmeister U, et al. Uremic toxicity: Present state of the art. Int J Artif Organs 2001; 24: 695-725
5. Raff AC, Meyer TW, Hostetter TH. New insights into uremic toxicity. Curr Opin Nephrol Hypertens 2008; 17: 560-565
6. Di Micco L, Marzocco S, Sirico ML, Torraca S, Di Iorio B. Does daily dialysis improve hypertension in chronic haemodialysis patients? Current Hypertension Reviews ISSN 2012; 8,(4), 291-295.
7. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, Chiang PH, Hsu CC, Sung, PK, Hsu YH, et al. All-cause mortality attributable to chronic kidney disease: Aprospective cohort study based on 462 293 adults in Taiwan. Lancet 2008; 371: 2173-2182.
8. Drey N, Roderick P, Mullee M, Rogerson M. A populationbased study of the incidence and outcomes of diagnosed chronic kidney disease. Am. J. Kidney Dis 2003; 42: 677-684.
9. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm, B. Aspects of immune dysfunction in end-stage renal disease. Clin. J.Am. Soc. Nephrol 2008; 3: 1526-1533
10. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: a systematic review. J. Am. Soc. Nephrol 2006; 17, 2034-2047
11. Marzocco S, Popolo A, Bianco G, Pinto A, Autore G. Proapoptotic effect of methylguanidine on hydrogen peroxidetreated rat glioma cell line. Neurochem Int 2010; 57(5): 518-524
12. Autore G, Marzocco S, Sorrentino R, Mirone V, Baydoun A, Pinto A. In vitro and in vivo TNFa synthesis by methylguanidine, an uremic catabolyte. Life Sciences 1999; 65 (11), 121-12
13. Marzocco S, Di Paola R, Serraino I, Sorrentino R, Meli R, Mattaceraso G, Cuzzocrea S, Pinto A, Autore G. Effect of methylguanidine in carrageenan-induced acute inflammation in the rats. Eur. J. Pharmacol 2004; 484 (2-3), 341-350
14. Marzocco S, Di Paola R, Genovese T, Sorrentino R, Britti D, Scollo G, Pinto A, Cuzzocrea S, Autore G. Methylguanidine reduces the development of non septic shock induced by zymosan in mice. Life Sci 2004; 75(12):1417-1433
15. Marzocco S, Di Paola R, Ribecco MT, Sorrentino R, Domenico B, Genesio M, Pinto A, Autore G, Cuzzocrea S. (2004) Effect of methylguanidine in a model of septic shock induced by LPS. Free Radical Res 2004; 38(11):1143-1153
16. Cioffi G, Dal Piaz F, De Caprariis P, Sanogo R, Marzocco S, Autore G, De Tommasi N. Antiproliferative triterpene saponins from Entada africana. J Nat Prod 2006; 69(9):1323-1329
17. Ben Jemia M, Kchouk ME, Senatore F, Autore G, Marzocco S, De Feo V, Bruno M. Antiproliferative activity of hexane extract from Tunisian Cistus libanotis, Cistus monspeliensis and Cistus villosus. Chem Cent J 2013; 5;7(1):47
18. Bianco G, Russo R, Marzocco S, Velotto S, Autore G, Severino L. Modulation of macrophage activity by aflatoxins B1 and B2 and their metabolites aflatoxins M1 and M2. Toxicon 2012; 59(6): 644-650
19. Cianchi F, Cuzzocrea S, Vinci MC, Messerini L, Comin CE, Navarra G, Perigli G, Centorrino T, Marzocco S, Lenzi E, Battisti N, Trallori G, Masini E. Heterogeneous expression of cyclooxygenase-2 and inducible nitric oxide synthase within colorectal tumors: correlation with tumor angiogenesis. Dig Liver Dis 2010; 42(1):20-27
20. Bianco G, Fontanella B, Severino L, Quaroni A, Autore G, Marzocco S, Nivalenol and deoxynivalenol affect rat intestinal epithelial cells: a concentration related study. Plos One 2012; 7(12) art. no. c52051
21. Menichini GC, Gonnella M, Barsotti G, Giovannetti S. "Determination of methylguanidine in serum and urine from normal and uremic patients", Experiention 1971; 27,1157-1158
22. Giovannetti S, Bigini M, Balestri PL, Navalesi R., Giagnoni P, De Matteis A, Ferro-Milone P, Perfetti C. "Uraemia-like syndrome in dogs chronically intoxicated with methylguanidine and creatinine", Clin. Sci 1969; 36, 445-452
23. Sakamoto M, Aoyagi K, Nagase S, Ishikawa T, Takemura, K, Narita M. "Methylguanidine synthesis by active oxygen generated by stimulated human neutrophils", Nippon Jinzo Gakkai Shi 1989; 8, 851-858
24. Sorrentino R., Sautebin L, Pinto A. "Effect of methylguanidine, guanidine and structurally relatedcompounds on constitutive and inducible nitric oxide synthase activity", Life Sci 1997; 61, 1283-1291
25. Cohen G., Hörl W.H. Immune Dysfunction in Uremia-An Update Toxins 2012; 4, 962-990
26. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994; 298, 249-258
27. Nathan C. Inducible nitric oxide synthase. What difference does it make? J. Clin. Invest 1997; 100 (10), 2417-2423
28. Popolo A, Autore G, Pinto A, Marzocco S. Oxidative stress in cardiovascular and renal disease. Free Radic Res 2013; 47:346-356
29. Moncada S, Higgs EA. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur. J. Clin. Invest 1991; 21(4), 361-374
30. Drapier JC, Hibbs Jr JB. Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J. Immunol 1988; 140 (8), 2829-2838
31. Dugo L, Marzocco S, Mazzon E, Di Paola R, Genovese T, Caputi AP, Cuzzocrea S. Effects of GW274150, a novel and selective inhibitor of iNOS activity, in acute lung inflammation. Br J Pharmacol 2004; 141: 979-87
32. Thiemermann C, Wu CC, Szabò C, Perretti M, Vane JR. Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock, Br.J. Pharmacol 1999; 110(1), 177-182
33. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark, Cohen G, De Deyn PP, Deppisch R, et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 2003;63: 1934-1943
34. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A. Normal and Pathologic Concentrations of Uremic Toxins. J. Am. Soc. Nephrol 2012; 23: 1258-1270
35. Vanholder R, Schepers E, Pletinck A, Neirynck N, Glorieux G. An update on protein-bound uremic retention solutes. J. Ren Nutr 2012; 22: 90-94
36. Marzocco S, Dal Piaz F, Di Micco L, Autore G, Torraca S, Sirico ML, Tartaglia D, Di Iorio B. Very low protein diet reduces Indoxjl Sulphate levels in Chronic kidney Disease. Blood Purif 2013; 13: 35: 196-201
37. Vanholder, R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J. A bench to bedside view of uremic toxins. J. Am. Soc. Nephrol 2008; 19: 863-870